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CHAPTER 1 
INTRODUCTION 
Global epidemiologic studies indicate that habitual ingestion of high levels of 
dietary salt is associated with elevated blood pressure (BP) (Stamler, 1997).  
Accordingly, one estimate suggests that approximately 58% of Americans with 
hypertension are salt sensitive (e.g., increased sodium intake elevates their arterial 
pressure and/or decreased sodium intake lowers their arterial pressure) (Weinberger, 
Fineberg, Fineberg, et al., 2001).  Salt sensitivity is more frequently observed in African 
American than in Caucasian subjects, and in older than in younger subjects (Luft, Miller, 
Grim, et al., 1991).  Salt sensitivity is so prevalent in African Americans that it is 
considered to be a “hallmark” of Black hypertension, as 73% of African American 
hypertensive patients are found to be salt sensitive (Svetkey, Chen, McKeown, et al., 
1997).  Salt sensitivity has also been linked to obesity (Flack, Grimm, Staffileno, et al., 
2002; Rocchini, Key, Bondie, et al., 1989), increased activation of the renin-angiotensin 
system (RAS), and relative deficiency of nitric oxide (NO) (Hall, Brands, Henegar, 1999; 
Adelman, 2002), in both African Americans and Caucasians.   
The mechanism or mechanisms resulting in salt-sensitive hypertension are 
multiple and include both activation of the RAS via increases in angiotensin II and 
reductions in the endogenous vasodilator, NO (Figure 1).  Oxidative stress reflected by 
release of reactive oxygen species (ROS) such as, superoxide anion (O2–) has several 
deleterious physiological effects, most importantly a reduction of NO bioactivity.  
Increased dietary sodium downregulates NO, upregulates vascular angiotensin II, and 
raises oxidative stress via upregulation of NADPH oxidase (Zhou, Adam, Jaimes, 2003; 
Boddi, Poggesi, Coppo, et al., 1998).  An important means of NO downregulation is 
2 
 
High Dietary Sodium
Decreased Dimethylarginine Dimethylaminohydrolase (DDAH)
Increased Reactive Oxygen Species (ROS)
Decreased Nitric Oxide (NO)
Salt Sensitivity1/Increased BP, Increased Vascular Tone and Vascular Stiffness
Increased Vascular Angiotensin II 
Increased Asymmetric Dimethylarginine (ADMA)
Obesity Dietary K+ Intake
Decreased 
Superoxide     
Dismutase
Increased NADPH Oxidase
Kininogen 
+
Kallekrein
Bradykinin 
 
Figure 1.  Proposed Model of the Sodium-Induced Reduction in Nitric Oxide and 
Elevation in Arterial Pressure in African Americans. Factors (i.e. obesity, high dietary 
sodium) associated with salt sensitivity increase vascular angiotensin II and 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and reduce superoxide 
dismutase (SOD), an important scavenger of reactive oxygen species.  The elevations 
of vascular angiotensin II and NADPH oxidase and reduction of SOD increase the 
presence of reactive oxygen species (ROS), which depress the expression and activity 
of dimethylarginine dimethylaminohydrolase (DDAH).  The DDAH enzyme catalyzes the 
degradation of asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide (NO) 
synthase.  Thus, DDAH depression by ROS results in the accumulation of ADMA, which 
decreases NO production.  In the setting of ad lib sodium intake, the reduction in NO 
results in impaired natriuresis that causes a rise in systemic pressure to augment renal 
pressure-natriuresis, thereby maintaining steady state volume homeostasis.  In the 
setting of ad lib potassium intake, potassium stimulates kallekrein release converting 
kininogen to bradykinin which increases NO release. 1Blood pressure (BP) rises to 
stimulate natriuresis thereby restoring tissue perfusion homeostasis due to the NO 
deficiency that has shifted the pressure-natriuresis curve rightward (to higher BP).  
Thus, in a sodium-replete environment, tissue perfusion homeostasis is maintained at 
the expense of higher BP. It is plausible but not known if the sodium-induced rise in 
ADMA is attributable to a parallel depression in DDAH by sodium.   
 
 
through asymmetric dimethylarginine (ADMA), an endogenous NO inhibitor, which is 
largely metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH).  
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The activity of DDAH is impaired by oxidative stress, thereby permitting ADMA to 
accumulate thus resulting in further inhibition of NO [↑ROS  ↓DDAH  ↑ADMA  
↓NO].  Increases in oxidative stress, reduction in DDAH activity, and augmented action 
of ADMA on depressing NO production represents a plausible mechanism in human salt 
sensitivity.  To date, we are unaware of studies that have examined the sodium-induced 
effect of DDAH activity resulting in this cascade. 
Therefore, the purpose of this study is to investigate and characterize the above 
mechanism through which salt-induced depression of NO synthesis occurs in 
normotensive African Americans.  The central hypothesis is that increased dietary 
sodium intake downregulates DDAH leading to increased ADMA which depresses 
NO production, resulting in a rise in BP.  I further postulate that ROS will increase 
with sodium exposure, resulting in downregulation of DDAH.  This initial study is 
the first to test whether increased sodium intake is associated with a reduction in DDAH 
activity, leading to an increase in ADMA, and a decrease in NO production as 
determined by fewer NO metabolites.  The study was conducted in healthy, 
normotensive African American men and women.   
Hypertension in African Americans is a major clinical and public health problem 
that contributes significantly to premature morbidity and mortality as well as to the 
shorter lifespan in African Americans compared to Caucausians.  Higher BP 
measurements in African Americans compared to Caucasians have been documented 
early in life, beginning in childhood (Muntner, He, Chen, et al., 2004).  The age-adjusted 
prevalence of hypertension (HTN) during 2006 among individuals aged 20 years and 
older in the total US population was 33.3% (73,600,000).  Non-Hispanic Blacks had the 
highest age-adjusted prevalence (44.4% men, 43.9% women), non-Hispanic Whites an 
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intermediate prevalence (34.1% men, 30.3% women), and Mexican Americans the 
lowest prevalence (23.1% men, 30.4% women) (Lloyd-Jones, Adams, Carnethon, et al., 
2009).  
Diet and lifestyle likely play important roles in the pathogenesis of HTN in African 
Americans and in the greater incidence of HTN relative to Caucasians.  African 
Americans, especially women, are less physically active, consume more calories and 
are more obese beginning in the pre-adult years than Caucasians (Burke, Savage, 
Manolio, et al., 1992; Sharp, Bell, Grunwald, et al., 2002).  Obesity, especially among 
women, is more common in African Americans than Caucasians (Ogden, Carroll, Curtin, 
et al., 2006).   
Salt sensitivity is associated with a rise in BP occurring during sodium loading 
and/or a fall in BP during sodium restriction that exceeds directionally appropriate 
random fluctuations in BP.  Salt sensitivity is more common in African American than 
Caucasian hypertensives and is also present, albeit to a lesser degree, in normotensive 
African Americans (Wright, Rahman, Scarpa, et al., 2003).  Nevertheless, more than 
50% of both African Americans and Caucasians with hypertension will manifest salt 
sensitivity (Peters and Flack, 2000).  Salt sensitivity is a very practical concern given the 
nearly ubiquitous intake of dietary sodium by Americans in general and African 
Americans in particular, that is far in excess of any known physiological need.  Even 
those African Americans with BPs in the normal range, have typically been found to 
manifest more salt sensitivity than Caucasians (Flack, Ensrud, Mascioli, et al., 1991).   
The acute phase of salt sensitivity is associated with transient plasma volume 
expansion and increased cardiac output leading to increased tissue perfusion.  The 
chronic phase of salt sensitivity is, however, characterized by a return of cardiac output 
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to normal and only those manifesting an increase in peripheral vascular resistance 
actually manifest a presssor response to sodium.  Arguably, salt sensitivity has been 
conceptualized as maintenance of tissue perfusion homeostasis at the expense of 
higher blood pressure levels that augment pressure-induced renal natriuresis.  Salt 
sensitivity increases at higher levels of BP, while plasma volume is simultaneously 
lower (frankly depressed) at higher BP levels.  Thus, it is unlikely that salt sensitivity is a 
physiological attempt to maintain intravascular homeostasis but rather is a physiologic 
means for normalizing tissue perfusion via an incompletely understood mechanism(s) of 
whole-body autoregulation.  The level of BP required to maintain steady state in/out 
tissue perfusion homeostasis can be influenced by factors such as nitric oxide 
deficiency and/or higher levels of angiotensin II, two factors that shift the pressure-
natriuresis curve to the right.  The pressure natriuresis relationship becomes less steep 
in those with salt sensitivity as higher arterial pressures are required to excrete any 
given amount of sodium compared to those who do not manifest salt sensitivity; it is the 
excretion of urinary sodium along with the rise in peripheral resistance that restores and 
maintains tissue perfusion homeostasis.  In individuals or groups prone to salt sensitivity 
(those with impairments in natriuresis), the consumption of a typical western diet that 
contains sodium far in excess of physiological requirements, will likely lead to sustained 
BP elevations.   
Although the physiological and genetic factors underlying salt sensitivity are 
increasingly understood, the mechanisms involved are not fully elucidated.  This 
experimental study will assess the effect of sodium loading on an important physiologic 
cascade that has been hypothesized to contribute to salt-sensitive hypertension.  This is 
an initial study used as basic exploratory work to establish a conceptual and plausible 
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model for future research.  The study will enhance our knowledge in the field of salt-
sensitive hypertension by potentially delineating a mechanism which can be targeted 
with lifestyle modifications (e.g., raised potassium intake) and via pharmacological 
means (e.g., DDAH stimulators) to prevent the rise in BP during habitually high dietary 
sodium intake. 
 
7 
 
CHAPTER 2 
BACKGROUND AND SIGNIFICANCE 
There are a number of obesity-related physiological effects that contribute to the 
intermediate BP phenotype, salt sensitivity (Rocchini, 2000; Hall, Henegar, Dwyer, et 
al., 2004)  as well as resistance to hypertensive drug therapy (Taler, 2005; Cushman, 
Ford, Cutler, et al., 2002) which is, in turn, at least partially mediated by salt sensitivity.  
Physical activity improves endothelial function, primarily via the augmented release of 
nitric oxide (NO) and reduced NO destruction attributable to lower levels of oxidative 
stress (Franzoni, ghiadoni, Galetta, et al., 2005; Rush, Denniss, Graham, 2005) and 
greater NO release from the vascular endothelium.  Long-term dietary patterns plausibly 
impact long-term trends in BP.  Increased dietary sodium intake raises BP, at least in 
susceptible people.  There is also evidence that increased dietary sodium intake 
augments vascular angiotensin generation (Boddi, Poggesi, Coppo et al., 1998) while, 
in salt-sensitive persons, reducing urinary NO metabolites (Cubeddu, Alfieri, Hoffmann, 
et al., 2000). 
Endothelium-dependent and endothelium-independent vascular responses have 
consistently been observed to be abnormal in African Americans compared to 
Caucasians (Stein, Lang, Nelson et al., 1997; Houghton, Philbin, Strogatz, et al., 2002).  
There are data suggesting that the bioavailable NO, the main determinant of 
endothelium-dependent vascular function, is lower in African Americans than 
Caucasians despite much higher levels of endothelial nitric oxide synthase (NOS) 
activity in the former (Malinski, 2005).  It appears that the synthesis of oxygen radicals, 
mostly via uncoupled endothelial nitric oxide synthase (eNOS) and to a smaller degree 
via NADPH oxidase, raises levels of oxidative stress, accelerates NO destruction, and 
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therefore leads to reduced NO bioavailability in African Americans (Malinski, 2005), and 
thus a rise in blood pressure.  The section below describes the pathophysiology of each 
mediator in the proposed mechanism involving the sodium-induced effect of DDAH 
activity in the cascade.of sodium-induced reduction in nitric oxide and elevation in 
arterial pressure in African Americans. 
Nitric Oxide Synthesis  
The major endothelium-derived vasoactive mediator is nitric oxide, an 
endogenous messenger molecule formed in healthy vascular endothelium from the 
amino acid precursor L-arginine.  Endothelium-derived nitric oxide (EDNO) regulates 
arterial tone through a dilator action on vascular smooth muscle cells that depends on 
soluble guanylyl cyclase activation and consequent increase in intracellular cyclic 3'5'-
guanosine monophospate (cGMP).  Reduced NO synthesis or increased inactivation 
likely plays an important role in increasing vascular tone, contributing to increased 
arterial resistance.  The uncoupling of eNOS from its cofactors through relative L-
arginine deficiency as well as by reduced tetrahydropterin, causes eNOS to produce 
reactive oxygen species (ROS) rather than NO, thereby reducing NO synthesis (Bevers, 
Braam, Post, et al., 2006) and increasing oxidative stress.  Nitric oxide inactivation 
owing to excess generation of reactive oxygen species, increased production of 
endogenous vasoconstrictors such as angiotensin-II and endothelin, decreased 
bioavailability of L-arginine, as well as defects in intracellular transduction pathways are 
several proposed mechanisms implicated in the pathophysiology of hypertension 
(Gokce, Keaney, Vita, 1998).   Lerman and colleagues demonstrated that after 6 
months of oral l-arginine supplementation, endothelium-dependent coronary blood flow 
reserve increased by 149% in response to acetylcholine when compared to placebo 
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group (Lerman, Burnett, Higano, et al., 1998).  Importantly, this improvement 
establishes a link between l-arginine at high doses and improved endothelial function 
that is almost entirely dependent on NO (even though it was not measured).  Relative l-
arginine deficiency is a known contributor to eNOS uncoupling. 
Nitric Oxide Metabolism 
Asymmetric Dimethylarginine (ADMA) 
A growing body of evidence indicates that in vivo accumulation of endogenous 
competitive nitric oxide synthase (NOS) inhibitors may reach sufficiently high 
concentrations under pathological disease conditions to shift the enzymatic milieu to 
disrupt synthesis of NO from L-arginine.  An important mechanism of NO antagonism is 
through asymmetric dimethylarginine (ADMA)—generated from posttranslational 
modification of arginine residues, which inhibits NO formation. Asymmetric 
dimethylarginine is one of three circulating endogenous analogues of L-arginine 
synthesized by methylation of arginine residues catalyzed by a group of enzymes 
termed protein arginine N-methyltransferases (PRMTs).  The other two methylarginines 
include N(G)-monomethyl-L-arginine (L-NMMA), which has low in vivo circulating levels, 
and symmetric dimethylarginine (SDMA) which does not inhibit NOS and is not 
hydrolyzed by dimethylarginine dimethylaminohydrolase (DDAH) enzyme (Figure 2).   
As the principal endogenous inhibitor of nitric oxide synthase, ADMA is an 
important regulator of NO formation.  Most NO deficient states are not characterized by 
low NO production but rather by high oxidative stress and high NO destruction rates.  
Increased ADMA levels correlate with disease severity in patients with peripheral 
arterial disease, and are linked to increased cardiovascular risk (Boger, Bode-Boger, 
Szuba, et al., 1998; Cooke, 2000).  ADMA levels are elevated in hypercholesterolemia, 
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hyperhomocysteinemia, diabetes mellitus, peripheral arterial occlusive disease, 
hypertension, chronic heart failure, coronary artery disease, pregnancy-induced 
hypertension and preeclampsia, erectile dysfunction, renal disease, as well as other 
clinical conditions (Lundman, Eriksson, Stuhlinger, et al., 2001; Boger, Bode-Boger, 
Thiele, et al., 1997; Kielstein, Boger, Bode-Boger, et al., 1999; Abbasi, Asagmi, Cooke, 
et al., 2001; Usui, Matsuoka, Miyazaki, et al., 1998; Surdacki, Nowicki, Sandmann, et 
al., 1999; Pettersson, Hedner, Milsom, et al., 1998).  ADMA also causes local 
vasoconstriction when infused intra-arterially, and increases systemic vascular 
resistance and impairs renal function when infused systemically (Figure 3).  More 
recently, Melikian and colleagues found that ADMA was the only independent correlate 
(inverse) of endothelial function and in a multivariable regression analysis race was the 
only independent determinant/correlate of plasma ADMA levels.  Healthy Black African 
men had approximately 33% higher ADMA levels in comparison with White European 
men (Melikian, Wheatcroft, Ogah, et al., 2007).  Also in healthy, young, normotensive 
Black African men, flow-mediated dilatation was significantly depressed when compared 
to White European men (5.2 ± 0.3 and 6.3 ± 0.4; p=0.02, respectively). 
 
Figure 2. Structure of l-arginine and endogenous methylarginines, N(G)-monomethyl-L-
arginine (L-NMMA), asymmetric dimethylarginine (ADMA) and symmetric  
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Figure 3. Schematic representation of the pathophysiological sequelae of elevated 
ADMA levels.  Reference: Rainer H. Boger M.D., Professor and Head, Clinical 
Pharmacology Unit, Institute of Experimental and Clinical Pharmacology. 
 
In salt-sensitive animal and human studies of hypertension, ADMA level 
correlates closely with elevation in arterial pressure (Matsuoka, Itoh, Kimoto, et al., 
1997).  More direct evidence that ADMA has a role in modulating cardiovascular 
hemodynamics was provided by Kielstein and colleagues (Kielstein, Impraim, Simmel, 
2004), who conducted a series of controlled experiments with graded intravenous 
infusions of ADMA in healthy individuals.  Evidence indicated that acute increases in 
plasma ADMA within a physiologically relevant range (2-10 mol/L) affected the 
cardiovascular system in healthy human subjects in vivo resulting in a sustained 
reduction in cardiac output, marked increase in mean arterial pressure, and systemic- 
and reno- vascular resistance, as well as a decrease in effective renal plasma flow.  
During ADMA infusion, Kielstein and colleagues also noted a significant reduction in 
concentrations of plasma cGMP, the main second messenger of NO (Kielstein, 
Impraim, Simmel, 2004).  Moreover, ADMA infusion caused significant sodium retention 
and an increase in blood pressure (BP) via a decrease in renal sodium excretion.  
Recently, Fang and colleagues (2006) demonstrated that high-salt significantly raises 
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plasma ADMA and BP while decreasing plasma NO synthesis and urinary NO excretion 
in normotensive salt-sensitive Asians after salt loading but not in the salt-resistant 
subjects. (Fang, Mu, He, et al., 2006).  This finding suggests that salt loading inhibits 
NO synthesis by increasing the production of ADMA in salt-sensitive subjects.  
Furthermore, potassium supplementation attenuated the effects of the high-salt diet on 
plasma ADMA, NO level, urinary NO excretion, and BP in normotensive salt- sensitive 
Asians; supplementing salt sensitive normotensive African Americans with potassium 
bicarbonate also has been shown to ameliorate salt sensitivity in a dose-dependent 
manner (Morris, Sebastian, Forman, et al., 1999).  The data in Asians suggest that 
potassium supplementation in normotensive salt- sensitive subjects prevents sodium-
induced depression in NO by preventing the salt-induced rise in ADMA.  The data in 
both Asians and African Americans demonstrate that potassium supplementation 
ameliorates the salt-induced rise in BP. 
In a nested, case-control study involving 150 middle-aged, non-smoking men, 
high ADMA levels were associated with a 3.9-fold elevated risk for acute coronary 
events (Valkonen, Paiva, Salonen, et al., 2001).  ADMA is a competitive inhibitor of 
eNOS and its inhibitory action can be overcome by increasing the concentration of the 
enzyme's substrate, L-arginine.  Circulating L-arginine concentrations have been found 
to be within the normal range in most clinical conditions associated with endothelial 
dysfunction.  Few patients experience pathologically low L-arginine concentrations.  
However, clinical and experimental evidence suggests that chronic elevation of ADMA 
causes relative L-arginine deficiency, even in the presence of "normal" L-arginine levels.  
These findings collectively suggest that chronic elevation of plasma ADMA acts as a 
modulator of vascular physiology under certain conditions. 
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Dimethylarginine Dimethylaminohydrolase (DDAH) 
Dimethylarginine dimethylaminohydrolase is an enzyme which converts ADMA 
into citrulline and dimethylamine (Ogawa, Kimoto, Sasaoka, 1987) 
[DDAHADMACitrulline+Dimethylamine] (Figure 4).  Although, plasma asymmetric 
dimethylarginine is partially cleared by the kidneys, the vast majority of ADMA is 
degraded by DDAH.  Of the total daily production of ADMA in humans, only 10% is 
excreted unchanged by the kidneys and the remaining 90% is metabolized by DDAH 
(Wilcken, Sim, Wang, et al., 2007).  The activity of DDAH is impaired by oxidative 
stress, which permits ADMA to accumulate.  A wide range of pathological stimuli 
induces endothelial oxidative stress such as oxidized low-density lipoprotein cholesterol, 
high dietary salt intake, inflammatory cytokines, hyperglycemia, and 
hyperhomocystinemia.  The attenuated activity of DDAH allows ADMA levels to rise 
thereby blocking NO production. 
 
 
Figure 4. Simplified scheme showing the main metabolic pathways for asymmetric 
dimethylarginine (ADMA). DDAH, dimethylarginine dimethylaminohydrolase; DMA, 
dimethylamine. (Baylis, 2008) 
 
Collectively, the ADMA-DDAH system appears to be involved in regulation of 
endogenous NO synthesis.  Firstly, Tojo and colleagues demonstrated that male 
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Sprague-Dawley rats on a low sodium diet had a significantly enhanced 
immunohistochemical expression of eNOS in renal vascular endothelium as well as 
enhanced DDAH renal expression as compared to high sodium rats.  Secondly, in 
erythropoietin (EPO)-induced hypertension, the postulated mechanism of elevated BP 
involves enhanced vascular reactivity and vasoconstriction.  Scalera and colleagues 
incubated endothelial cells for 24 hours in the presence of EPO, and analyzed 
measures of reactive oxygen species (ROS), ADMA, and activity of DDAH.  They found 
that after endothelial cells were exposed to EPO, ADMA concentration significantly 
increased in a dose-dependent manner versus control and was accompanied by a 
significant reduction in NO synthesis and an increase in oxidative stress, as measured 
by intracellular ROS.  Furthermore, addition of antioxidant (pyrrolidine dithiocarbamate) 
preserved DDAH activity and reduced ADMA accumulation.  In summary, these studies 
support the idea that sodium influences NO metabolism in a manner consistent with 
raising levels of oxidative stress and DDAH activity appears to be sensitive to oxidative 
stress.  However, it remains unclear if sodium-induced changes in oxidative stress can 
actually be linked to downregulation of DDAH in humans. 
Nitric Oxide Homeostasis 
Reactive Oxygen Species, Superoxide Dismutase, and NADPH Oxidase 
Superoxide anion (O2–) and other ROS are constant products of cellular 
metabolism.  However, the development of oxidative stress is determined by the 
balance between the production of ROS such as O2– mainly by NADPH oxidase 
(Taylor, Glocka, Liang, et al., 2006) and degradation by the antioxidant defense system 
involving superoxide dismutase (SOD).  Superoxide is usually instantly reduced by the 
enzyme SOD normally present in living tissues (Kitiyakara, Chabrashvili, Chen, et al., 
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2003).  Scavenging of O2– significantly reduces BP in several experimental models of 
hypertension (Schnackenberg, Welch, Wilcox, 1998; Welch, Blau, Xie, 2005), especially 
those associated with salt sensitivity (Manning, Meng, Tian, 2003; Howard, Patterson, 
Mullins, et al., 2005).  Additionally, superoxide dismutase helps preserve the activity of 
NO by scavenging O2–, thus increasing the half-life of NO.  The mechanism for NO 
degradation in blood vessels is its interaction with O2–, leading to the formation of 
peroxynitrite (Jung, Marklund, Xia, et al., 2007).  Previous studies have indicated that 
inhibition of NO generation during high-salt intake leads to the development of salt-
sensitive hypertension and the impairment of kidney function (Tolins, Shultz, 1994; 
Yamada, Sassaki, Fujihara, 1996; Nakanishi, Hara, Nagai, 2002).  Thus, increases in 
oxidative stress as evidence by increased O2– level resulting in NO deficiency appear to 
contribute to the development of salt sensitivity.   
The exact mechanism whereby the endogenous level of O2– is increased during 
NOS inhibition is not yet clear.  The uncoupling of eNOS from its cofactors causes 
eNOS to produce O2– instead of NO.  A recent study by Taylor and colleagues (2006) 
found that excess renal medullary interstitial superoxide production in salt-sensitive rats 
contributed to salt-induced hypertension, and that NADPH oxidase was the major 
source of the excess superoxide.  By administering a NADPH oxidase inhibitor, 
apocynin, there was a reduction in medullary interstitial superoxide as well as mean 
arterial pressure in salt-sensitive rats.  Both NO and O2– are constant products of 
cellular metabolism, and both of these molecules are constantly interacting with each 
other in biological tissues (Modlinger, Wilcox, Aslam, 2004).  Normally, O2– in the tissue 
is kept to a minimal level by the antioxidative function of SOD.  However, when NO 
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production is diminished in the tissue or when eNOS uncouples generating ROS instead 
of NO, it is expected that this balance may be altered allowing O2– accumulation in the 
tissue (Majid, Nishiyama, Jackson, 2004).   
In a study by Meng and colleagues, a 3-week intravenous infusion of Tempol, a 
membrane-permeable SOD mimetic, markedly blunted the salt-induced increase in 
arterial pressure in Dahl salt-sensitive rats by approximately 22 mm Hg (Meng, Cason 
Gannon, et al., 2003).  Superoxide anion release was significantly higher in salt 
sensitive high-sodium rats compared with salt sensitive low-sodium rats, suggesting that 
a high sodium intake in salt-sensitive rats causes increased oxidative stress.  Tempol 
markedly decreased O2– release in the renal cortex and medulla, and the magnitude of 
the reduction of O2– release by Tempol was significantly greater in salt sensitive high-
sodium rats.  Moreover, Tempol infusion in the Dhal salt-sensitive rats on a high salt 
diet delayed the onset and reduced the magnitude of HTN.  However, the mechanism of 
the amelioration of hypertension in the high-sodium/Tempol salt-sensitive rats was not 
clear.   
Schnackenberg and colleagues previously showed that an acute bolus injection 
of Tempol reduced arterial pressure and renal vascular resistance in the spontaneous 
hypertensive rat (SHR) but not the Wistar-Kyoto rat and that this response was blocked 
by nitro-L-arginine methyl ester, an inhibitor of NO synthases, but not by 
norepinephrine.  This implies that Tempol might prevent inactivation of NO by O2–, thus 
increasing the bioavailability of NO (Schnackenberg, Welch, Wilcox, 1998).  
Furthermore, salt loading induces oxidative stress in the kidneys of normal rats; 
Kitiyakara and colleagues reported that the increased oxidative stress during high salt 
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was accompanied by increased NADPH oxidase activity and decreased renal 
expression of the mRNA for intracellular and mitochondrial SOD.  Overall, there seems 
to be a delicate balance between the production and destruction of O2– with NO 
bioactivity. 
All mammalian tissue contains three forms of superoxide dismutase (SOD), 
differing primarily in their locations (Beyer, Imlay, and Fridovich, 1991).  SOD-1 is 
localized in the cytosol, SOD-2 in the mitochondria, and SOD-3 in the extracellular 
space.  Importantly, extracelluar SOD-3 activity is ~100-fold higher in the vessel wall 
than in other tissues.  Thus, in the vessel wall, SOD-3 plays a critical role in regulating 
the vascular re-dox state in the extracellular space.  Strålin and colleagues, 
demonstrated that SOD-3 is a very important component of the total superoxide 
dismutase in the vessel wall, comprising one-third to one-half of the total vascular SOD 
activity (Strålin, Karlsson, Johansson, et al., 1995).  Additionally, the predominant site of 
production of SOD-3 is the smooth muscle cell in healthy vessels.   Thus, an important 
function of extracellular SOD-3 in the arterial wall may be the preservation of bioactivity 
of NO with its antiatherogenic and vasodilating effects.  In support of this, Jung and 
colleagues revealed that a shortage of endogenous vascular extracellular SOD activity 
occurs in situations of combined oxidative and nitrosative stress (Jung, Marklund, Xia, 
et al., 2007).   
Reactive Oxygen Species and Dimethylarginine Dimethylaminohydrolase  
Oxidative stress by S-nitrosylation (presence of a reactive cysteine residue in the 
active site of DDAH) inactivates DDAH (Leiper, Murray-Rust, McDonald, et al., 2002), 
which provides an important mechanism leading to upregulation in the levels of ADMA, 
thereby limiting further NO generation.  Isoprostanes are prostaglandin-like substances 
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that are produced in vivo independently of cyclooxygenase enzymes, primarily by free 
radical-induced peroxidation of arachidonic acid.  Isoprostanes have been shown to be 
extremely accurate markers of oxidative stress in vivo, as isoprostane levels increase 
dramatically in experimental animal models of oxidant injury and these levels can be 
suppressed by administration of antioxidants (Morrow, Roberts, 1996).  Environments 
which elevate intracellular oxidative stress including hyperglycemia and 
hyperhomocysteinemia have also demonstrated impaired activity of DDAH (Lin, Ito, 
Asagami, et al., 2002; Stuhlinger, Tsao, Her, et al., 2001).  On the other hand, several 
antioxidants (i.e., all-trans-Retinoic acid, polyethylene glycol-conjugated SOD [PEG-
SOD]) increased expression of DDAH, thus DDAH is considered an oxidant-sensitive 
enzyme (Achan, Tran, Arrigoni et al., 2002; Lin, Ito, Asagami, et al., 2002). 
Nitric Oxide and Natriuresis 
In Dahl salt-sensitive rats, sodium chloride loading induces endothelial 
dysfunction and hypertension, whereas BP and vasodilator responses remain normal 
when these animals consume a low-salt diet.  In this animal model of hypertension, L-
arginine prevents the development of hypertension, and this protection can be 
overcome by an inhibitor of NOS (Chen and Sanders, 1991).  It is now understood that 
renovascular NO production modulates salt and water excretion, and that salt-sensitive 
hypertension may reflect an impairment of NO action (Shultz and Tolins, 1993).  In 
humans, the fall in pressure with L-arginine administration is more pronounced in salt-
sensitive subjects (Campese, Amar, Anjali, et al., 1997).  From a clinical perspective, 
these findings strongly suggest that L-arginine exerts a significant hypotensive effect in 
patients who manifest salt sensitivity, presumably via augmentation of NO production. 
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Obesity 
In all likelihood, obesity contributes significantly to HTN risk in all racial/ethnic 
populations, and many racial and ethnic minorities manifest obesity disproportionately.  
Approximately 80% of people with HTN in the United States are overweight or obese 
(BMI ≥ 25 kg/m2).  In Black women the prevalence of extreme obesity (BMI > 40 kg/m2) 
is almost 1 in 6, a prevalence that is ~3 – 4-fold higher than that of White and Hispanic 
women (Hensrud, Klein, 2006).  There are marked ethnic and age-based differences in 
the rates of weight accumulation.  Relative to White women the onset of obesity 
occurred sooner for Black and Hispanic women.  After 28 years of age, Black men 
develop obesity more rapidly than White men.  Anthropometric measures, such as 
obesity, especially in women, can also influence biologic systems involved in BP 
regulation and the expression of pressure-related target-organ damage (i.e. chronic 
renal injury).  For example, obesity is a major anthropometric correlate of salt sensitivity 
in Blacks and Whites (Flack, Ensrud, Mascioli, et al., 1991). 
Vascular Stiffness 
Blood pressure represents the confluence of vascular properties such as arterial 
stiffness, endothelial dysfunction, cardiac output, peripheral vascular resistance and 
extracellular/intravascular volume.   Blood pressure is a function of blood flow and 
vascular resistance (i.e., BP= cardiac output x total peripheral resistance).  In clinical 
practice, pressure is defined in terms of systolic (SBP) and diastolic (DBP) blood 
pressure, which refers to a pulsatile phenomenon, with SBP and DBP representing the 
extremes of the blood pressure oscillation around a mean BP value.  These are 
quantitative measures of blood pressure, however, blood pressure and flow fluctuate 
during the cardiac cycle.  The elastic and geometric properties of the arteries cause the 
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arterial pressure pulse to change its shape as it travels along the arterial tree.  Thus, 
hemodynamic information contained in the shape of the arterial pressure pulse reflects 
the type of interaction between the heart as a pump and the arterial system as the load, 
and can complement the conventional measurement of BP.   
Arterial stiffness is an important determinant of cardiovascular risk, and the 
augmentation index is a measure of systemic arterial stiffness derived from the 
ascending aortic pressure waveform.  In normal individuals the reflected wave returns to 
the central aorta late in diastole (augmenting coronary flow which occurs solely in 
diastole) and thus there is relatively little amplification of the aortic pressure.  As blood 
vessels become stiff due to age-related processes, and/or other co-morbidities, such as 
hypertension, hyperlipidemia, diabetes mellitus, and peripheral vascular diseases, the 
pulse wave is transmitted more rapidly and returns to the heart during systole, resulting 
in a greater augmentation of the central aortic systolic pressure (Gatzka, Cameron, 
Kingwell, et al., 1998; Wilkinson, Prasad, Hall, et al., 2002).   
Theoretical Framework 
Based on the review of literature, a plausible physiologic model is presented 
(Figure 1) to explain the relationship between sodium intake and nitric oxide activity 
resulting in salt sensitive increases in blood pressure. 
Summary of Literature 
Epidemiological and clinical studies demonstrated a clear relationship between 
salt intake and hypertension.  However, the BP response to changes in dietary salt are 
heterogeneous among individuals.  Dietary sodium raises oxidative stress and reactive 
oxygen species contribute to impaired endothelial function in salt-sensitive rats (Zhou, 
et al., 2003, Laffer et al., 2006).  The activity of DDAH is impaired by oxidative stress 
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(Leiper, Murray-Rust, McDonald, et al., 2002), thus permitting ADMA to accumulate and 
resulting in the inhibition of NO.  Although it is known that sodium stimulates oxidative 
stress and modulates the renin-angiotensin system, in both humans and rats; it is 
currently unknown whether dietary sodium has an effect on DDAH activity.  The 
purpose of this study is to investigate and assess if there is a sodium-induced effect on 
DDAH activity which would represent a plausible mechanism in human salt sensitivity. 
Purpose and Aims 
The purpose of this study is to test the hypothesized physiologic model to 
determine the mechanism involved in sodium-induced depression of NO synthesis and 
elevation in blood pressure in African American individuals.  Three specific aims will be 
tested. 
Specific Aims: 
Aim 1:  Determine the correlation between DDAH activity, levels of ADMA, and urinary 
NO metabolites following dietary salt loading.   
Hypothesis 1a: Dietary salt loading correlates with a reduction in DDAH activity 
(urine dimethylamine [DMA]:urine asymmetrical dimethylarginine [ADMA], 
is used as a marker of DDAH activity/expression; GC-Mass Spec). 
Hypothesis 1b:  A reduction in DDAH activity correlates with a rise in ADMA 
(urine ADMA; GC-Mass Spec) levels, and subsequent reductions in 
urinary levels of NO metabolites following dietary salt loading. 
Aim 2:  Determine the dietary sodium-induced changes in DDAH activity, circulating 
levels of ADMA, and NO metabolites, and their relationship to changes in arterial 
stiffness (AS) and blood pressure (BP) following dietary salt loading.   
Hypothesis 2:  Dietary salt loading correlates with a reduction in DDAH activity 
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and an increase in ADMA levels and a reduction in NO metabolites 
resulting in an increase in AS (SphygmoCor) and BP (cuff). 
Aim 3:  Determine the association between DDAH activity and ADMA levels and their 
correlation with the presence of the gene polymorphism (superoxide dismutase-3 [SOD-
3]), circulating markers of oxidative stress, and free radical following dietary salt loading.   
Hypothesis 3:  Dietary salt loading correlates with increased measures of 
oxidative stress (total 8-isoprostanes) and free radical (nitrotyrosine) and a 
reduction in DDAH activity and increase in ADMA levels, with these 
sodium-induced changes being greatest in subjects without the SOD-3 
genotype. 
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CHAPTER 3 
METHODS 
Design 
The study used an integral cross-over experimental design with four-phases 
lasting 20 weeks.  The current study was a sub-study associated with an ongoing NIH-
trial “Obesity, Nitiric Oxide, and Salt Sensitivity” (ONOSS) (NIH/NIEHS 1P50ES012395-
01).  Healthy, normotensive African American men and women from the ongoing NIH-
trial ONOSS were used as the population study sample.  The ONOSS study was a 39-
week study of healthy African American men and women aged 35 years and older who 
were overweight or obese [body mass index (BMI) > 25 and < 40 kg/m2].   
Sample 
Overall, 210 African American participants were recruited to the ONOSS study 
from 14 metro-Detroit community sites to participate in the study, and the data were 
collected between 2004-2008.  The recruitment strategies used included local health 
fairs, bus advertisements, and radio spots.  This study was reviewed and approved by 
the Wayne State University, Institutional Review Board and signed informed consent 
was obtained from all participants prior to their participation. 
To be included in the overall study, participants needed to be normotensive, 
African American men and women aged 35 years and older with non-hypertensive BP 
levels based on average cuff BP readings at the third eligibility visit and who were 
overweight or obese with a BMI of ≥ 25 and < 40 kg/m2, with the urinary 
sodium:creatinine ≤ 1.1 at the third eligibility visit.  The exclusion criteria included the 
following:  hypertension according to JNC VI co-morbidity definitions > 140/90 mm Hg, if 
there was kidney disease [estimated glomerular filtration rate (GFR) < 60 mL/min/1.73 
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m2], or diabetes mellitus [fasting blood sugar (BS) > 126 or take diabetes medication or 
random BS > 200 mg/dl], psychiatric illness or dementia, heart failure, angina pectoris, 
intermittent claudication, valvular heart disease, myocardial infarction, coronary artery 
bypass graft, coronary or peripheral angioplasty, history of life threatening cardiac 
arrhythmias, peripheral vascular surgery within the past 6 months, use of non-steroidal 
anti-inflammatory drugs > 4 days/week, liver function tests > 1.5 x upper normal, 
albumin < 3.5, planned to move > 50 miles or travel extensively from the area during the 
next 12 months, urine albumin:creatinine ratio > 500, night-shift work, use of 
supplemental vitamins/minerals/herbs, any difficulty swallowing, or positive pregnancy 
test (given to premenopausal women who have not had a hysterectomy and have not 
been surgically sterilized).  They were also excluded if currently taking cardiovascular 
medications including lipid lowering drugs, medications for mental illness, > 3 alcoholic 
drinks per day, > 6 restaurant meals per week, oral steroids or nitrates, or if they 
refused to sign informed consent form, refused venipuncture, refused to comply with 
overnight urine collections, and refused to take study capsules.    
Of the original 72 participants recruited in the sub-study, 63 participants were 
included at baseline visit, and only 43 participants were included in the analyses after 
application of exclusion criteria and participant drop outs.  The population consisted of 
normotensive (BP < 140/90 mm Hg), overweight (body mass index = 25 – 39.9 kg/m2) 
African American men and women aged 35 years and older.  The majority of 
participants were female (87%) and the mean age was 45 years. 
Study Protocol 
The current sub-study was conducted in four phases (Figure 5, Table 1) and 
incorporated a randomized, blinded cross-over design.  In Phase I:  Dietary Orientation, 
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a low-sodium plus weight maintenance dietary regimen was introduced for each 
participant during the initial 8 weeks of the study, representing the pre-randomization 
phase.  A registered dietitian counseled each participant at their initial visit and follow-up 
clinic visits where she advised participants to maintain a food diary; and weekly follow-
up telephone encounters were completed on each participant throughout the remaining 
time of the study.  Participant vital signs (i.e., blood pressure, pulse rate, and weight) 
were measured every other week.  In Phase II: Randomization, participants were 
randomized to either a 4-week placebo or a 100 mmol sodium loaded diet [1,800 
grams].  During the blinded 4-week salt loading period, participants received sodium 
chloride capsules that contained 11.1 mmol of sodium [placebo was an inactive 
ingredient].  Participants took 3 capsules three times a day during sodium and placebo 
supplementation.  Participants were encouraged to take their capsules with food.  At the 
end of the 4th week, lab samples and measurements were obtained and represented the 
post-randomization phase of either placebo or sodium exposure.  Participants continued 
the low-sodium diet during the treatment period with maintenance of body weight 
achieved.  Intakes of potassium and calcium were as expected to be, close to the 
average for older African Americans in the US population (54 mmol/day potassium and 
550 mg/day calcium) (Kant, Graubard, Kumanyika, 2007).  In Phase III Wash-out, all 
participants underwent a wash-out period during the ensuing 4 weeks.  Participant 
blood pressure, pulse rate, and weight were measured every other week, and they 
continued to undergo dietary counseling.  In Phase IV: Cross-over, participants were 
randomized to either the 4-week remaining placebo or 100 mmol sodium loaded diet.  
At the end of the 20th week (final visit), lab samples and measurements were obtained 
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and represented the post-randomization phase of either the remaining placebo or 
sodium exposure.   
Throughout the study, participants continued the low-sodium diet during the 
intervention period with maintenance of body weight.  Compliance to the diet and 
treatment capsules were monitored by determining the urinary sodium:creatinine ratio in 
three pooled overnight urine samples, once before the sodium/placebo supplementation 
in Phase II and twice thereafter, following the sodium and placebo loading. 
The choice of a study design that manipulates a single dietary nutrient, sodium 
chloride, on the background of a fixed dietary intake that is typical of free-living 
individuals, is purposeful.  Studies like the DASH diet intervention (Milan, Mulatero, 
Rabbia, et al., 2002; Volmer, Sacks, Ard, et al., 2001) have demonstrated that 
simultaneously changing multiple dietary nutrients is an effective means of lowering BP.  
A DASH-like design is, however, less well suited for understanding the physiological 
effect of a single dietary nutrient.  Thus, we have chosen to hold constant, as best we 
can, potential modifiers of the salt-BP response (e.g., potassium, calcium, fat) and to 
discern the impact of physiological modifiers and mediators of the BP response to 
dietary sodium.  The chosen population, African Americans, have a high prevalence of 
nitric oxide deficiency, obesity, salt sensitivity, and endothelial dysfunction (Winkleby, 
Kraemer, Ahn, et al., 1998; Flack, Grimm, Staffileno, et al., 2002). 
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Figure 5. Four-Phase Protocol Design This flow diagram represents the cross-over 
design used in the current sub-study for 20 weeks. During Phase I, participants 
underwent 8 weeks of dietary orientation to a low-sodium plus weight maintenance diet.  
This dietary regimen was continued throughout all of the phases of the study.  Phase II 
occurred after the initial 8 weeks of dietary orientation, where participants were blindly 
randomized to either the placebo or sodium supplementation cohort for the following 4 
weeks.  Next, all participants underwent a Phase III wash-out period for 4 more weeks, 
prior to the final phase IV cross-over phase where participants were crossed-over into 
the remaining cohort, either placebo or sodium supplementation.  The final visit for this 
sub-study was at the end of the phase IV randomization placebo/sodium 
supplementation, representing the end of the 20th week.  This protocol followed a 
randomized cross-over design to control for time and order effects.   
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Table 1.  Protocol for Four-Phase Sub-Study 
XXXXXXXXX (every other visit)Phone visit /Dietary 
Counseling
XXXXXX (every other visit)Clinic Visit
XXCollect study capsules
XXXDispense study capsules 
OR broth
XXXPulse Wave Velocity
XXXPlatelet Nitric Oxide 
Generation
XXXOvernight Urinary Na, K, 
Creatinine
XXXFree Radicals
XXXUrinary Nitric Oxide
XXXPlasma Isoprostanes
XXDimethylarginine
dimethylaminohydrolase
XXAsymmetric 
dimethylarginine
XXXPhysical Activity
XXDietary Assessment
XXXAmbulatory BP
XXXXXX (every other visit)Vitals/BMI
2019181716151413121110980--7Week
Phase IV:  
Placebo/Sodium              Phase III:  Wash-Out                                        Phase II:  Placebo/Sodium                                    
Phase I:  Low 
Sodium DietPERIODS FOR ANALYSIS
 
This chart details all visits and explicitly describes the protocol for this sub-study.  Under each visit 
phase lists the lab/measures, or data which is to be collected for each successive visit through all four 
phases of the 20-week study. 
Study Measures 
1) Dietary Intake Assessment:  Dietary assessments were completed by the registered 
dietitian once before the sodium/placebo supplementation began in Phase II and at 
the end of the final visit (end of 20th week).  Dietary data is thought to be under-
reported in obese subjects (Kretsch, Fong, Green, et al., 1999).  The records were 
analyzed with the Nutrition Data System, research version of the software 
(University of Minnesota, Nutrition Coordinating Center).  At the beginning and end 
of the study, a Food Frequency Questionnaire (Block’98 Food Frequency 
Questionnaire) was also administered to capture usual eating patterns over the last 
12 months (Block, Woods, Potosky, et al., 1990).  The intake of electrolytes was 
estimated (e.g. calcium, potassium, and magnesium). 
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2) High Dietary Sodium:  During the blinded 4-week salt loading period, participants 
received sodium chloride capsules that contained 11.1 mmol of sodium [placebo 
was an inactive ingredient].  Participants took 3 capsules three times a day during 
sodium and placebo supplementation. 
3) Reactive Oxygen Species is measured using two variables: Total 8-isoprostanes 
and free radicals 
Total 8-Isoprostanes:  8-Isoprostane level in serum appears to be a good marker of 
oxidative stress in humans, and immunoassays for these oxidation products are 
suggested to be more specific than chromatographic methods (Proudfoot, Barden, 
Mori, et al., 1999).  Only total 8-isoprostane was measured because free 8-
isoprostane determination requires much larger sample volumes due to its low levels 
and there was excellent correlation between total and free 8-isoprostane in plasma.  
Total 8-isoprostane is expected to be a good measure of lipid peroxidation levels, 
based on published data from human studies (Proudfoot, Barden, Mori, et al., 1999; 
Morrow, Frei, Longmire, et al., 1995).  Total 8-isoprostane levels in plasma were 
measured only once at baseline.  Total 8-isoprostane plasma levels were measured 
using an EIA kit from Cayman Chemical Co. (Ann Arbor, MI) using a modified Sep-
Pak procedure. 
Free Radical:  Free radical was measured once before the sodium/placebo 
supplementation in Phase II, considered a baseline value.  The type of free radical 
generated in the arterial wall was estimated from quantization of nitrotyrosine.  
These protein degradation products are generated from nitric oxide, hydroxyl radical 
and hypochlorous acid, respectively.  Nitrotyrosine was quantified by gas 
chromatography with mass spectral detection (GC/MS).  It has been proposed that 
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assay of oxidized amino acids such as tyrosine in plasma may be a marker of 
oxidative stress relevant to cardiovascular diseases (Heinecke, 2002).  Free radicals 
are critical to the interpretation of the study results because they destroy NO.  Also 
joint consideration of free radical and NO production will permit characterization of 
the impact of the relative balance between desirable NO and mostly undesirable free 
radical generation on BP responses to dietary sodium manipulations. 
4) Superoxide Dismutase (SOD):  The 47C>T(A16V) polymorphism in SOD2 has been 
identified as functional.  Accordingly, it is linked to a 30-40% decrease in enzyme 
activity.  The 637 C>G (Arg213Gly) mutation in SOD3 has been linked to an 8-10 
fold increase in enzyme activity.  SOD is an antioxidant enzyme, thus increased and 
reduced activity is, respectively, associated with greater and lesser anti-oxidant 
effects.  The latter would lead to higher levels of oxidative stress. 
5) Dimethylarginine dimethylaminohydrolase (DDAH):  DDAH activity was indirectly 
measured by the quantification of endogenous dimethlyamine (DMA), product of 
degraded ADMA by DDAH enzyme, and ADMA (DMA/ADMA molar ratio index for 
creatinine, micromol/mmol creatinine) (Chobanyan, Thum, Suchy, et al., 2007).  
Urine DMA was measured twice during the sub-study after the dietary sodium and 
placebo supplementation phases, simultaneously with ADMA.  Urine biomonitoring 
data was adjusted to the constant creatinine concentration to correct for variable 
dilutions among spot samples.  Dimethlyamine in human urine by gas 
chromatography-mass spectrometry (GC-MS) was determined by the Institute for 
Clinical Pharmacology, Hannover Medical School, Hannover, Germany. 
6) Asymmetric dimethylarginine (ADMA):  ADMA levels fall as DDAH levels rise.  
ADMA was measured twice during the study, after dietary sodium and placebo 
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supplementation (end of the placebo phase represents the “baseline” ADMA level).  
The ratio of urine ADMA to urine creatinine (ADMA/Cr) was used in the statistical 
analyses to control for urine dilution, a standard method when evaluating urine 
biomarkers.  ADMA in human urine by GC-MS was determined by the Institute for 
Clinical Pharmacology, Hannover Medical School, Hannover, Germany. 
7) Urinary Nitric Oxide (NO):  Urinalysis of total nitrate and nitrite concentration was 
determined by the Institute for Clinical Pharmacology, Hannover Medical School, 
Hannover, Germany.  Total nitrate and nitrite metabolites in urine, which represents 
crude nitric oxide production, were measured by first converting nitrate to nitrite 
using nitrate reductase and then treating with Griess reagents to convert nitrite into a 
deep purple azo compound (Tsikas, 2007).  Photometric measurement of the 
absorbance of the azo compound was at 540 or 550 nm.  The detection limit for 
nitrate/nitrite assay (80 μl) and nitrite assay (100 μl) was 2.5 μM and 2.0 μM, 
respectively, and the mean interassay CV was 3.4%.  In non-contaminated urine, 
nitrate would be approximately 99% of the sum of nitrate and nitrite.  Total nitrate 
and nitrite metabolites in urine were expressed as an excretion rate in units µmol/8 
hours (Tsikas, 2007).  The ratio of urine NO to urine Cr (NO/Cr) was used in the 
statistical analyses to control for urine dilution, a standard method when evaluating 
urine biomarkers.  NO metabolites were measured once before the sodium/placebo 
supplementation in Phase II and twice thereafter, following the sodium and placebo 
loading.  Prior to these visits, participants were counseled to adhere to a low nitrate 
diet for the four days prior to the urine collection. Written materials were provided 
along with telephone counseling.  Urinary nitrate measures represented nitric oxide 
production, a key predictor and outcome variable in this study.    
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8) Obesity – height/weight- body mass index (BMI):  Height was obtained at the initial 
visit, while weight was measured using a standard balance beam scale.  Height and 
weight are necessary to determine BMI. 
9) There were two outcome measures of interest: arterial stiffness and blood pressure: 
Arterial Stiffness (AS):  Measurement of AS was performed once before the 
sodium/placebo supplementation in Phase II and twice thereafter, following the 
sodium and placebo loading.  AS was measured non-invasively using the 
SphygmoCor system (AtCor Medical, Australia).  AS was measured by calculating 
augmentation index (AI).  AS is positively correlated with AI (the difference between 
the first and second pressure peaks divided by pulse pressure).  AS should be 
affected by NO metabolism, oxidative stress, and/or dietary sodium manipulations.   
Resting Blood Pressure:  All BP measurements were obtained using a protocol that 
was adapted from the American Heart Association Recommendations for Human BP 
Determination (Perloff, Grim, Flack, et al., 1993).  Three pressure readings were 
recorded within a 5-minute period taking the average of these 3 readings to record 
as the BP measurement for that visit.  BP was measured at every clinic visit for all 
participants, however the BP at the end of sodium and placebo periods were utilized 
in the analysis.  BP is the primary study response variable.  Systolic blood pressure 
(SBP) was chosen as the primary response variable because it is measured more 
precisely than diastolic BP (DBP), and because it more closely related to target-
organ injury and pressure-related mortality, even after consideration of 
measurement error, than DBP (He, et al., 1999).  Further, preliminary studies 
suggest that increased dietary sodium exposure has a relatively greater impact on 
SBP compared to DBP, at least on a per mm Hg basis.   
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10) Urinary Sodium:Creatinine Ratio:  Urinary sodium was quantified, as an estimate of 
changes in dietary intake, by determining the urinary sodium:creatinine ratio in three 
pooled overnight urine samples, once before the sodium/placebo supplementation in 
Phase II and twice thereafter, following the sodium and placebo loading. 
Statistical Analysis 
Descriptive analyses for means, medians, standard deviations (SD), and 95% 
confidence intervals (CI) were conducted for all continuous variables (i.e., age, body 
mass index, blood pressure) while proportional distributions were examined for all 
categorical variables.  Continuous variables were examined for skewness/normality 
using Shapiro-Wilk statistic.  Continuous data that deviate significantly from normality 
were transformed to the natural logarithm to approximate a normal distribution prior to 
analysis.  The paired t test was used to compare the exposure effects at end of the 
sodium and placebo study periods.  Subsequently, Pearson correlations were utilized to 
quantify associations, and were considered significant at the 5% significance level.  The 
outcome measures of this study were the continuous variables (DDAH, ADMA, urinary 
NO metabolites, BP, and AS).  The power analysis has been estimated for significance 
level of 5% and showed that 66 study patients have more than 80% power for a change 
in SBP.  Missing data was random and participants with missing variables in regards to 
the main outcome measures were eliminated from the analysis, resulting in a loss of 
power.  All analyses including appropriate statistics, p-values, and graphs were reported 
using Statistical Analysis Software (SAS, version 9.1). 
Data Analysis  
Specific Aim 1:   
After both dietary sodium and placebo supplementation, the relationship of the 
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change in DDAH activity (urine dimethylamine [DMA]: asymmetrical dimethylarginine 
[ADMA], used as a marker of DDAH activity/expression) to the change in the levels of 
urinary ADMA and urinary NO metabolites, after dietary salt loading was examined.  
Paired t test was used to compare the differences between the end of sodium and 
placebo study periods.  Pearson correlations were utilized to quantify associations, and 
were considered significant at the 5% significance level.  The variables were divided by 
creatinine in the statistical analyses to minimize timing errors related to the collection of 
the urine samples, a standard method when evaluating urine biomarkers.  The 
magnitude of timing error is much less if you take the amount of sodium in 
urine/creatinine in urine.  Urinary biomonitoring data are typically adjusted to the 
constant creatinine concentration to correct for variable dilutions among spot samples. 
Specific Aim 2:   
The associations of sodium-induced changes in DDAH activity, circulating levels 
of ADMA and urinary NO metabolites after dietary salt loading in relation to the changes 
in BP and arterial stiffness, were quantified.  Paired t test was used to compare the 
differences at the end of the sodium and placebo study periods; SBP and DBP were 
used separately in analyses involving BP.  The variables were divided by creatinine in 
the statistical analyses to minimize timing errors related to the collection of the urine 
samples. 
Specific Aim 3:   
Levels of DDAH activity and ADMA were correlated with levels of circulating 
markers of oxidative stress (total 8-isoprostanes), and free radical (nitrotyrosine) after 
salt loading.  Paired t test was used to compare the differences at the end of the sodium 
and placebo study periods.  Independent sample t test was used to compare the levels 
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of oxidative stress and free radical at a given point and time between the two groups.  
The variables were divided by creatinine in the statistical analyses to minimize timing 
errors related to the collection of the urine samples. 
Additional analyses:   
There were a wide range of values in addition to a very narrowly distributed data 
set, thus additional analyses utilizing z-scores was done.  These differences in 
distributions made it difficult to judge similarities or significant differences among 
categories in the data sets, however after standardizing with z-scores, the data results 
remained relatively unchanged. 
Quality Control 
All persons involved in handling laboratory samples were trained in the 
appropriate procedures of processing, labeling, and storage by Clandestine Laboratory 
Investigators Association (CLIA) personnel standards to assure that laboratory 
personnel had the appropriate training and experience to adequately perform.  In order 
to minimize variability of urinary nitrate/nitrite levels participants were instructed to follow 
a low nitrate/nitrite diet for 4 days prior to each urinary nitrate/nitrite collection.  The 
mean coefficient of variation has been shown to be to be significantly higher within 
individuals during a “free” diet (40 ± 9%) compared with a “low nitrate/nitrite” diet (10 ± 
1%) (P = 0.02).  The research staff performing BP measurements underwent periodic 
training on BP measurement to verify reliability and accuracy of BP measurement 
techniques.  Weekly telephone contact was maintained with participants throughout a 
large portion of the study to maximize the diet intervention effect and to minimize losses 
to follow-up. 
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Actual Difficulties and Limitations 
Several (N=18) patients dropped out after the first intervention period and thus 
did not receive the second treatment, while 11 participants withdrew from the overall 
study.  Several patients experienced side-effects with the sodium intervention (i.e., 
nausea, swelling) which contributed to the dropout rate.  This made within-subject 
comparison impossible and was particularly important as withdrawal reduced the 
statistical power.  This further complicated the concept of intent-to-treat analysis as 
several patients randomized completed the first period, but not the second period.   
Ethical Aspects 
There were minimal risks to human subjects associated with the sub-study.  
Some of the interview questions could be considered sensitive.  No study procedures 
were performed until informed consent was obtained.  The Core Director ensured that 
the informed consent process was appropriately carried out, reviewed the consent 
forms for completeness, and ensured their confidentiality by locking them in a file in her 
office.  Core personnel and study personnel from each project had access to the files for 
their project, but no one else could access it without the subjects’ permission.  All 
procedures were performed by appropriately trained personnel according to study 
protocols.  Interviewers underwent training so that they were able to perceive and 
appropriately deal with any sensitivity participants may have to questionnaire items.  We 
did not anticipate needing medical or emergency intervention in this minimal risk study, 
but there was a part-time internist and a part-time physician’s assistant assigned to the 
Core, who were available by pager in addition to a hospital “code” team assigned to the 
Core.  For all subjects, unique study identification numbers were utilized.  Internal 
Review Board approved all aspects of the study. 
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CHAPTER 4 
RESULTS 
Descriptive Statistics 
Overall, there were no statistically significant differences in patient characteristics 
at baseline in the 63 participants recruited into the sub-study; however only 43 
participants were included in the analyses after application of exclusion criteria and 
participant drop outs.  The majority of participants were female (87%) and the mean age 
was 45 years (Tables 2a and 2b).  Average measures of BP and hemodynamic 
parameter did not differ by gender.  Mean cuff SBP and DBP were within normal range 
of SBP < 140 mmHg and DBP < 90 mmHg. 
Table 2a.  Baseline Patient Characteristics  
Patient Characteristics Randomized Treatment Sequence 
 Placebo-Salt Mean (SD) Salt-Placebo Mean (SD)
Age, years 45.3 (5.0) 45.9 (7.0) 
Female, n(%) 28 (90%) 28 (87.5%) 
Systolic blood pressure, mmHg 116.6 (9.4) 118.6 (9.7) 
Diastolic blood pressure, mmHg 76.4 (4.8) 77.6 (6.3) 
Body Mass Index, kg/m² 32.7 (4.5) 32.0 (3.9) 
Current smoker, n(%) 3 (9.7%) 4 (12.5%) 
Cholesterol, mg/dL 196.1 (32.8) 206.9 (42.7) 
Triglyceride, mg/dL 85.3 (33.4) 93.9 (41.4) 
(N=63; Placebo-Salt N=31; Salt-Placebo N=32) 
 
Table 2b.  Characteristics of Patients Included in the Crossover Analysis 
Patient Characteristics Randomized Treatment Sequence 
 Placebo-Salt Mean (SD) Salt-Placebo Mean (SD)
Age, years 48.7 (4.4) 49.6 (7.4) 
Female, n(%) 16 (100%) 22 (91.7%) 
Systolic blood pressure, mmHg 115.5 (9.2) 120.5 (12.6) 
Diastolic blood pressure, mmHg 78.5 (7.0) 79.2 (7.7) 
Body Mass Index, kg/m² 32.3 (3.9) 32.0 (4.1) 
Current smoker, n(%) 1 (6.25%) 2 (8.7%) 
Cholesterol, mg/dL 188.3 (35.8) 198.8 (60.8) 
Triglyceride, mg/dL 93.3 (38.0) 100.1 (40.7) 
 (N=43; Placebo-Salt N=17; Salt-Placebo N=26) 
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Specific Aim 1 
Aim 1:  Determine the correlation between DDAH activity, levels of ADMA, and urinary 
NO metabolites following dietary salt loading.   
Hypothesis 1a: Dietary salt loading correlates with a reduction in DDAH activity 
(urine dimethylamine [DMA]:urine asymmetrical dimethylarginine [ADMA], 
used as a marker of DDAH activity/expression; GC-Mass Spec). 
Hypothesis 1b:  A reduction in DDAH activity correlates with a rise in ADMA 
(urine; GC-Mass Spec) levels, and subsequent reductions in urinary levels 
of NO metabolites following dietary salt loading. 
The mean of the difference between the two treatment periods (sodium – 
placebo) in DDAH activity and NO metabolites was -0.83 (95% CI -2.7-1.1, SD = 4.4) 
and -11.65 (95% CI -38.2-14.9, SD = 61.6), respectively, indicating that post-sodium 
DDAH activity and NO metabolites tended to be slightly lower after sodium.  As 
hypothesized, the DDAH activity and NO metabolite levels did decrease following 
exposure to sodium supplementation, however, using paired t-test the difference 
between DDAH activity and NO metabolite levels were not statistically significant 
(DDAH: t = -0.87, DF = 84, p = 0.39; NO: t = -0.88, DF = 65.64, p = 0.38).  The mean 
DDAH:creatinine ratio following the placebo phase of the study was 13.45 (SD = 5.0); 
following the sodium supplementation phase of the study the mean DDAH:creatinine 
ratio was 12.62 (SD = 3.8), representing a 6.17% decrease (Figure 6).  The mean 
NO:creatinine ratio following the placebo phase of the study was 101.40 (SD = 76.2); 
following the sodium supplementation phase of the study the mean NO:creatinine ratio 
was 89.71 (SD = 42.3), representing an 11.53% decrease (Figure 7).  Thus, the data 
suggest but do not confirm the hypothesis that DDAH activity and NO metabolite levels 
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are significantly lower after sodium supplementation. 
 
Figure 6.  DDAH:creatinine levels post-sodium and pre-sodium exposure 
 
 
Figure 7.  NO:creatinine levels post-sodium and pre-sodium exposure  
 
The mean ADMA:creatinine ratio following the placebo phase of the study was 
3.97 (SD = 1.4); following the sodium supplementation phase of the study the mean 
ADMA:creatinine ratio was 3.81 (SD = 0.8), representing a slight 4.03% decrease 
(Figure 8).  The mean of the difference in ADMA:creatinine ratio was -0.164 (95% CI -
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0.7-0.3, SD = 1.2), indicating that post-sodium ADMA:creatinine ratio tended to be 
slightly lower after sodium, however using paired t-test the difference between the two 
treatment periods (sodium – placebo) was not statistically significant (t = 0.64, DF = 
66.9, p = 0.52).   
 
Figure 8.  ADMA:creatinine levels post-sodium and pre-sodium exposure 
Pearson correlation coefficient between the difference in NO:creatinine ratio and 
ADMA:creatinine ratio between the two treatment periods was positively correlated (r = 
0.35; p = 0.02) (Table 3).  Therefore, contrary to the initial hypothesis, ADMA was 
positively associated with NO metabolite level in the urine.  ADMA inhibits NO and this 
inhibitory action may have stimulated NO production, however NO activity would still be 
reduced because of the high ADMA activity. 
Furthermore, the correlation coefficient for the difference in NO:creatinine ratio 
and DDAH activity level between the two treatment periods demonstrated a strong, 
positive correlation (r = 0.90; p = <0.0001).  Thus, heightened DDAH activity was 
significantly associated with a greater production of NO metabolites.   
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Additional analysis comparing the change in urine sodium:creatinine ratio after both 
dietary sodium and placebo supplementation: 
Correlation of the change in urine sodium:creatinine ratio and ADMA:creatinine 
ratio between the two treatment periods was non-significant (r = 0.07; p = 0.83).  
Furthermore, the correlation of the change in urine sodium:creatinine and 
DDAH:creatinine ratio (r = -0.41; p = 0.18), and urine sodium:creatinine and 
NO:creatinine ratio (r= -0.37; p = 0.23) at the end of the two treatment periods were not 
significant.   
Table 3. Pearson Correlation Coefficients 
 ∆NO:Creatinine ∆DDAH:Creatinine ∆ADMA:Creatinine ∆Sodium:Creatinine 
∆NO:Creatinine 1.00 
 
43 
0.90 
  <0.0001 
43 
0.35 
0.02 
43 
-0.37 
0.23 
12 
∆DDAH:Creatinine 0.90 
                 
<0.0001  
43 
1.00 
 
43 
0.19 
0.21 
43 
-0.41 
0.18 
12 
∆ADMA:Creatinine 0.35 
0.02 
43 
0.19 
0.21 
43 
1.00 
 
43 
0.07 
0.83 
12 
∆Sodium:Creatinine -0.37 
0.23 
12 
-0.41 
0.18 
12 
0.07 
0.83 
12 
1.00 
 
12 
ADMA: Asymmetric Dimethylarginine; DDAH: Dimethylarginine Dimethylaminohydrolase; NO: Nitric 
Oxide 
Specific Aim 2 
Aim 2:  Determine the dietary sodium-induced changes in DDAH activity, circulating 
levels of ADMA, and NO metabolites, and their relationship to changes in arterial 
stiffness (AS) and blood pressure (BP) following dietary salt loading.   
Hypothesis 2:  Dietary salt loading correlates with a reduction in DDAH activity 
and an increase in ADMA levels and a reduction in NO metabolites 
resulting in an increase in AS (SphygmoCor) and BP (cuff). 
The mean of the difference in SBP and DBP respectively, was +2.8 mm Hg (95% 
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CI -2.2-7.7, SD = 11.8) and +0.8 mm Hg (95% CI -2.6-4.1, SD = 7.9).  As hypothesized, 
the SBP and DBP levels were increased slightly following exposure to sodium 
supplementation, however, using paired t-test the difference between the two SBP and 
DBP levels did not reach statistical significance (SBP:  t = 1.11, DF = 88, p = 0.27; DBP:  
t = 0.45, DF = 88; p = 0.66) (Figure 9).  Nevertheless, the difference in 
sodium:creatinine ratio was directly proportional to the difference in both SBP and DBP 
between the two treatment periods (r = 0.75, p = 0.01; r = 0.49; p = 0.13, respectively); 
however, SBP was the only significant correlation and it was positively associated with 
the sodium:creatinine ratio; these data suggest that the magnitude of the observed BP 
change was less than predicted because of a lesser between-study period change in 
the urinary sodium:creatinine ratio (Table 4). 
 
Figure 9.  Blood pressure changes after sodium exposure  
43 
 
Table 4. Pearson Correlation Coefficients with BP 
 ∆SBP ∆DBP 
∆NO:Creatinine 0.18 
0.40 
24 
-0.06 
0.79 
24 
∆DDAH:Creatinine -0.06 
0.76 
24 
-0.15 
0.48 
24 
∆ADMA:Creatinine 0.37 
0.07 
24 
0.03 
0.90 
24 
∆Sodium:Creatinine 0.75 
0.01 
11 
0.49 
0.13 
11 
ADMA: Asymmetric Dimethylarginine; DDAH: Dimethylarginine 
Dimethylaminohydrolase; NO: Nitric Oxide; SBP: Systolic Blood 
Pressure; DBP: Diastolic Blood Pressure 
Association of sodium-induced changes in ADMA:creatinine ratio after dietary salt 
loading in relation to changes in BP 
The difference in ADMA:creatinine ratio was also directly proportional to the 
difference in SBP between the two treatment periods (r = 0.37, p = 0.07).  The 
correlation between the difference in ADMA:creatinine ratio and SBP was borderline 
significant. 
Association of sodium-induced changes in DDAH: creatinine ratio and NO: creatinine 
ratio after dietary salt loading in relation to changes in BP  
The correlation between the difference in NO:creatinine ratio to the difference in 
SBP and DBP between the treatment periods were non-significant (SBP: r = 0.17; p = 
0.40; DBP: r = -0.06; p = 0.79.  Also, the correlation between the difference in 
DDAH:creatinine ratio to the difference in SBP and DBP were also non-significant (SBP: 
r = -0.06; p = 0.76; DBP: r = -0.15; p = 0.48, respectively). 
Association of sodium-induced changes in arterial stiffness measures 
The mean of the difference in augmentation index was +11.79 (95% CI -3.4-26.9, 
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SD = 19.5), a 14.9% difference, indicating that post-sodium augmentation index tended 
to be higher after sodium.  As hypothesized, the augmentation index did increase 
following exposure to sodium supplementation, however, using paired t-test the 
difference between the two treatment periods was suggestive though not statistically 
significant (t = 1.60, DF = 26, p = 0.12).   
Pearson correlation coefficient of the change in ADMA:creatinine ratio was not 
significantly correlated with the change in augmentation index (r = 0.27; p = 0.42) (Table 
5) between the treatment periods.  On the other hand, the correlation of the change in 
DDAH:creatinine ratio and the change in augmentation index between the treatment 
periods was significantly negatively correlated (r = -0.61; p = 0.04).  Thus, heightened 
DDAH activity was strongly associated with a lower augmentation index, as the 
measure of arterial stiffness, as expected.  Furthermore, the change in NO:creatinine 
ratio was negatively correlated with the change in augmentation index (r = -0.59; p = 
0.05); thus, supporting the hypothesis that NO metabolite levels are inversely 
associated with arterial stiffness.   
Table 5. Pearson Correlation Coefficients with Augmentation Index  
 ∆AI 
∆NO:Creatinine -0.59 
 0.05 
11 
∆DDAH:Creatinine -0.61 
 0.04 
11 
∆ADMA:Creatinine 0.27 
0.43 
11 
ADMA: Asymmetric Dimethylarginine; AI: 
Augmentation Index; DDAH: Dimethylarginine 
Dimethylaminohydrolase; NO: Nitric Oxide;  
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Specific Aim 3 
Aim 3:  Determine the association between DDAH activity and ADMA levels and their 
correlation with the presence of the gene polymorphism (superoxide dismutase-3 [SOD-
3]), circulating markers of oxidative stress, and free radical following dietary salt loading.   
Hypothesis 3:  Dietary salt loading correlates with increased measures of 
oxidative stress (total 8-isoprostanes) and free radical (nitrotyrosine) and a 
reduction in DDAH activity and increase in ADMA levels, with these 
sodium-induced changes being greatest in subjects without the SOD-3 
genotype. 
Nitrotyrosine and isoprostane levels were analyzed at baseline only (these 
oxidative markers were not measured post-sodium, only at baseline), thus cross-
sectional analyses were done to determine the correlation between these oxidative 
stress markers and ADMA:creatinine, DDAH:creatinine, and NO:creatinine ratio levels.  
ADMA:creatinine, DDAH:creatinine, and NO:creatinine ratios were not significantly 
correlated to either baseline nitrotyrosine nor  isoprostane levels. 
The assay for the SOD-3 polymorphism was not completed, as the Genomics 
division noted that it has a very low frequency in Caucasians and even lower in African 
Americans.  Given our small sample size and African American population, it was 
unlikely that I would find any heterogeneity.  
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CHAPTER 5 
Discussion 
The study population was a cohort of mostly young (mean age 45 years, SD = 
6.0), female (87%), African Americans who were normotensive, and overweight.  
Several potentially important findings exist in this study.  First of all, in a cohort of 
young, overweight, African American normotensive women, the data overall trended in 
the direction hypothesized.  The DDAH level and NO metabolites came down after 
sodium exposure, while the blood pressure rose and the augmentation index increased 
by almost 12% after sodium exposure, though not statistically significant.  The 
difference in sodium:creatinine ratio was directly proportional to the change in BP (SBP: 
p = 0.01; DBP p = 0.13), which likely mediated the BP effect.  Additionally, nitric oxide 
metabolites and DDAH levels were positively correlated to each other (r = 0.90; p = 
<0.0001), and changes in both DDAH and NO levels were negatively correlated to 
changes in augmentation index (DDAH: r = -0.61; p = 0.04; NO: r = -0.59; p = 0.05).  As 
expected, after sodium loading the DDAH and NO levels decrease while the 
augmentation index increases reflecting an increase in arterial stiffness.   
On the other hand, the change in NO was positively correlated with the change in 
ADMA (r = 0.35; p = 0.02).  In speculating a physiologic pathway for this discrepancy, 
ADMA inhibits NO and this inhibitory action may have stimulated NO production, 
however NO activity would still be reduced because of the high ADMA activity.  Thus, 
the rise in NO levels would not be able to overcome the effects of ADMA inhibition.  
Furthermore, the expected effect upon the oxidant-sensitive enzyme DDAH was not 
detected, as there was no significant evidence of redox-sensitive inhibition of the 
enzyme DDAH activity by the free radicals.  Although several studies have linked 
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increased oxidative stress to high salt intake in animals (Zhou, Adam, Jaimes et al., 
2003; Tian, Moore, Braddy, et al., 2007; Swei, Lacy, DeLano, et al., 1997), the human 
data are more limited.  In a study by Laffer and colleagues, acute (one-day) sodium 
loading and depletion using an established protocol produced corresponding increases 
and decreases, respectively, in plasma F2-isoprostanes in salt sensitive hypertensive 
subjects.    
Citizens of acculturated societies, given free access to salt, invariably consume 
between 100 and 200 mmol of sodium daily (INTERSALT, 1998).  Several meta-
analyses indicate that among hypertensive and older subjects, a 3- to 5-mm Hg systolic 
and approximately 1-mm Hg diastolic change in pressure is associated with a 75 to 100 
mmol/24 hour difference in sodium intake (Midgley, Matthew, Greenwood, et al., 1996; 
Graudal, Galloe, Garred, 1998).  The effect on younger and normotensive subjects is 
less with approximately 2 to 3 mm Hg for systolic and <1 mm Hg for diastolic.  Thus, this 
is in line with the BP effect which occurred in our study.  The major reason we likely did 
not see as much physiological effect on BP and other measures was because of the 
less than predicted difference in the urine sodium:creatinine ratio between the treatment 
periods, as well as the smaller sample size. 
On the other hand, the inability to demonstrate a strong relationship between 
sodium intake and blood pressure within a population in which habitual sodium intake is 
relatively generous (>120 mmol/day) does not deny such a relationship as individual 
differences in susceptibility or temporal factors may influence the blood pressure 
response to such intake.  In other words, individuals who are susceptible to salt-induced 
alterations in blood pressure may be balanced by those in whom such an effect is 
negligible.  Alternatively, a long period of exposure to increased sodium intake may be 
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required for blood pressure manifestations to be apparent, while the age of the 
population studied may influence the observations as well.  For these reasons, 
information from more dramatic manipulations of sodium balance in an older cohort may 
provide greater insight into the relationship between salt and blood pressure. Overall, 
substantial variation in intake (75 to 100 mmol/24 hours) can produce measurable but 
modest changes in blood pressure.  The effect appears to be more substantial in older 
subjects and in those with higher pressures.   
Age has been found to be significantly related to salt sensitivity of blood pressure 
in the majority of studies.  Only a few studies using interventions to assess salt 
sensitivity have included large enough numbers and a sufficient age range of subjects to 
be able to identify such a relationship.  Increasing salt sensitivity has been noted with 
increasing age in several other studies (Weinberger, Miller, Luft, 1986; Osanai, 
Kanazawa, Yokono, 1993; Overlack, Ruppert, Kolloch, et al., 1995).  Additionally, this 
relationship appears to be stronger in hypertensive than in normotensive individuals 
(Weinberger, Fineberg, 1991).  The mean age of participants in our study was 45 years, 
and thus our data may be skewed given our young cohort.  Given the youth of our 
population, the occurrence of salt-sensitive hypertension is less prevalent, and would 
reflect as less significance in the study findings. 
Hypertensive patients, as a group, are significantly more salt sensitive than 
normotensive individuals (Weinberger, Miller, Luft, 1986).  Given that the participants 
were all normotensive, the sample size would have to be significantly greater for 
significance to be present.  Based on the results for DDAH levels between salt loaded 
(mean = 12.62, SD = 3.8) versus placebo groups (mean = 13.45, SD = 5.0), and 
hypothesizing that people with higher salt load have lower DDAH levels compared to 
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lower salt loaded participants; a post-hoc power analysis was done to determine the 
level of power actually achieved to see if that’s a factor in the non-significant findings.  
The power analysis revealed that 204 participants would be required for the crossover 
study design to achieve 0.85 statistical power (alpha = 0.05) of detecting a mean 
difference in DDAH levels between salt loaded and placebo groups.  Therefore, the 
selection criteria likely impacted these results, thus reflecting a major limitation to the 
study, as the prevalence of salt-sensitive individuals is lower in normotensive versus 
hypertensive patients.   
By and large several limitations impacted the significance level in the study, 
including a smaller sample size than expected, thus the difference noted may not have 
allowed for significant changes to be established.  Another major shortcoming was likely 
the inadequate difference in the urine sodium:creatinine ratio at the end of the two time 
periods.  There may have been a lack of effect as there was not a full sodium load 
secondary to lack of compliance with capsule ingestion.  Several participants 
experienced side effects (i.e., nausea) due to the size of the capsules, or they may have 
forgotten to take their capsules.  When taking placebo, and presumably consuming a 
100 mmol/day sodium diet, the urinary sodium:creatinine ratio was 0.8522.  The 
supplementation of an additional 100 mmol/day should double the urine 
sodium:creatinine ratio; however, the urine sodium:creatinine ratio at the end of sodium 
was only 1.2651.  While the expected difference between the two treatment periods was 
0.8522; the observed difference that was statistically significant was 0.4130.  Thus, 
0.4120/0.8522 = 0.485 or 48.5% of the expected difference between the two treatment 
periods was ACTUALLY observed.  The conclusion is that sodium supplementation did 
indeed occur to a statistically significant degree but to a level that was slightly less than 
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50% of predicted.  This is clearly related to the problem with taking capsules, perhaps of 
such a large size, as well as consuming high levels of sodium in concentrated amounts 
causing nausea.  This exercise makes some assumptions that may not be entirely 
accurate - the linking of the urine sodium:creatinine ratio of 0.8522 to a dietary intake of 
100 mmol of sodium per day - however, it is a very reasonable exercise to estimate how 
short the dietary intake fell short of the projected amount if everyone would have taken 
the sodium.  In essence, the physiological changes seen occured with ~ 50 mmol of 
difference in dietary sodium exposure between the two treatment periods.  Additionally, 
the patient population was basically normotensive, and this may have impacted the 
change in DDAH, ADMA, and NO levels, as many patients may not have been salt 
sensitive.   
Overall, in a cohort of young, overweight, African American normotensive 
women, sodium exposure was directly proportional to the difference in BP and there 
was a reduction in DDAH level and NO metabolites, with significant indirect correlations 
between DDAH, NO and augmentation index.  This study attempted to characterize a 
novel mechanism of action through which salt-induced depression of NO synthesis may 
occur in normotensive African American individuals.  Despite lack of significance in the 
differences of DDAH, ADMA, and NO between the treatment groups, the combined 
group results trended in the direction of the central hypothesis that increased dietary 
sodium intake downregulates DDAH and depresses NO production, and revealed a rise 
in BP and vascular stiffness.  This initial study is the first demonstrating the trend that 
increased sodium intake was associated with a reduction in DDAH activity, and a 
depression in NO metabolites in healthy, normotensive African Americans.  The findings 
provide beginning evidence of the proposed linkages, but further study is warranted 
51 
 
given the aforementioned limitations.  This was a small study used as basic exploratory 
work to establish a plausible model for future research.  The study advances knowledge 
in the field of salt-sensitive hypertension by delineating a mechanism of action which 
may be further studied to potentially target the prevention of elevated blood pressure. 
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ABSTRACT 
 
EFFECT OF DIMETHYLARGININE DIMETHYLAMINOHYDROLASE IN TE 
DEVELOPMENT OF SALT SENSITIVITY 
by 
SAMAR ABDULLA NASSER 
May 2011 
Advisor: Dr. John Flack 
Major:  Physiology 
Degree: Doctor of Philosophy    
Salt sensitivity is associated with a rise in blood pressure (BP) occurring during 
sodium loading and/or a fall in BP during sodium restriction that exceeds random 
fluctuations in BP.  Salt sensitivity is more common in African American than Caucasian 
hypertensives and is also present, in normotensive African Americans.  The mechanism 
or mechanisms resulting in salt-sensitive hypertension are multiple and include both 
activation of the renin angiotensin system via increases in angiotensin II and reductions 
in the endogenous vasodilator, nitric oxide (NO).  An important means of NO 
downregulation is through asymmetric dimethylarginine (ADMA), an endogenous NO 
inhibitor, which is largely metabolized by the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH).  The activity of DDAH is impaired by oxidative stress, 
thereby permitting ADMA to accumulate thus resulting in further inhibition of NO.  
Increases in oxidative stress, reduction in DDAH activity, and augmented action of 
ADMA on depressing NO production represents a plausible mechanism in human salt 
sensitivity.  The study investigates and characterizes the above mechanism through 
which salt-induced depression of NO synthesis occurs in normotensive African 
66 
 
Americans.  The study population was a cohort of mostly young (mean age 45 years, 
SD = 6.0), female (87%), African Americans who were normotensive, and overweight.  
The DDAH level and NO metabolites came down after sodium exposure (6.17% and 
11.53%, respectively), while the BP rose (SBP: +2.8 mm Hg; DBP +0.8 mm Hg) and the 
augmentation index (a measure of arterial stiffness) increased by almost 12% after 
sodium exposure, though not statistically significant.  The difference in 
sodium:creatinine ratio was directly proportional to the change in BP (SBP: p = 0.01; 
DBP p = 0.13), which likely mediated the BP effect.  Additionally, NO metabolites and 
DDAH levels were positively correlated to each other (r = 0.90; p = <0.0001), and 
changes in both DDAH and NO levels were negatively correlated to changes in 
augmentation index (DDAH: r = -0.61; p = 0.04; NO: r = -0.59; p = 0.05).  As expected, 
the DDAH and NO levels increased while the augmentation index decreased reflecting 
a reduction in arterial stiffness.  Overall, in a cohort of young, overweight, African 
American normotensive women, sodium exposure was directly proportional to the 
difference in BP and there was a reduction in DDAH level and NO metabolites, with 
significant indirect correlations between DDAH, NO, and augmentation index.  Despite 
lack of significance in the differences of DDAH, ADMA, and NO between the treatment 
groups, the combined group results trended in the direction of the central hypothesis 
that increased dietary sodium intake downregulates DDAH and depresses NO 
production, resulting in a rise in BP and vascular stiffness.  This initial study is the first 
demonstrating the trend that increased sodium intake was associated with a reduction 
in DDAH activity, and a depression in NO metabolites in healthy, normotensive African 
Americans.   
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